Maricann Group Inc (CSE:MARI), producer and distributor of medical cannabis in Canada, announced on September 5 th that it has secured a second-site sales license from Health Canada for its location in Burlington, Ontario. The company‘s first license applies to its Langton, Ontario location. Maricann plans to keep its cultivation, extraction, formulation and distribution operations in Langston, and centralize its marketing, sales, research and client service to Burlington.
The new location will help the company streamline sales and marketing processes, including potential same day delivery to Toronto, and next day delivery across Canada. They also plan to roll out a new customer live chat service soon to spur growth and consumer satisfaction. Maricann will also establish an analytical laboratory in Burlington to assist in medical research. They expect this will help them scale the business more efficiently.
Maricann was founded in 2013 and is based in Toronto and Munich, Germany. It is vertically integrated and focused on the medical market. Its current fully-funded expansion project will grow its producing area to 517,000 sq ft, with a capacity to grow up to 57,245 kg of dry cannabis flower per year.
Source: MarketWired, Sept 5 2017